Blog #4: Companies Sharing Good News in Financial Reports

Many companies in the pharmaceutical industry are sharing good news in their financial reports for the first half of 2012. My company, Novo Nordisk, has lots of good news to share. They are doing very, very well and growing at a very large rate. Their financial statements for the first nine months of 2012 indicate that Novo Nordisk saw a 34% increase in operating profits. Their sales grew 18%. Net profit increased by 26% and earning per share increased by 31% (Novo Nordisk 2012).

TEVA had some good news to report in their financials as well. In one year, their net revenue increased from $12,636 to $15,068. TEVA acquired a Danish Company on October 25, 2012 for $26 million (TEVA 2012).

Abbott Laboratories also had good news to report in their most recent financial statement. In 2011, their net sales worldwide increased form $35.2 million to $38.9 million. Their operating cash flow increased from $8.7 million to $9 million. Abbott grew global sales by 10.5% and increased ongoing earnings per share by 11.8% (Abbott Laboratories 2011).

On the other hand, Pfizer did not have much good news to share. In their financial reports for the third quarter of 2012, their reported revenues from 2011 to 2012 decreased by 16%. Their adjusted income decreased by 16%. Their net income decreased by 14% (Pfizer 2012).

Works Cited

 



Abbott Laboratories (2011). 2011 Annual Report. Retrieved from

      http://media.corporate-ir.net/media_files/irol/94/94004/Proxy_Page/AR2011.pdf.

Novo Nordisk (31 October 2012). Financial Report for Period 1 January 2012 to 30 September 2012.

      Retrieved from  

      http://webmedia.novonordisk.com/nncom/images/investors/investor_presentations/2012/

      Interim_report/PR121031_Q3_2012_UK.pdf. 

Pfizer (2012). Pfizer Reports Third-Quarterly 2012 Results. Retrieved from

      http://www.pfizer.com/files/investors/presentations/q3performance_110112.pdf.

TEVA (November 2012). TEVA Pharmaceutical Industries Limited. Retrieved from

      http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-reportsAnnual.